CDK4 and cancer: The G1/S transition is considered as an effective target for cancer therapies; for instance, palbociclib, a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that leads to G1/S arrest, was found to significantly prolong the progression-free survival of patients with hormone-receptor-positive metastatic breast cancer [15, 16].